Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674477 | 0.88 | CES1 (0.33) | TDP1MMEL1CES1NCEH1 | |
| SCHEMBL4673270 | 0.88 | ALDH1A1 (0.39) | TDP1CES1NCEH1TP53POLB | |
| SCHEMBL4671114 | 0.88 | CES1 (0.44) | MMEL1CES1NCEH1MME | |
| SCHEMBL4677023 | 0.87 | CYP11B1 (0.34) | CES1NCEH1 | |
| SCHEMBL4674748 | 0.86 | HCAR2 (0.42) | CES1NCEH1PTGDR2TP53PIN1 | |
| SCHEMBL4673272 | 0.86 | XDH (0.41) | CES1NCEH1 | |
| SCHEMBL4675749 | 0.85 | ALDH1A1 (0.42) | CXCR3PTGDR2TP53 | |
| SCHEMBL4676745 | 0.83 | TDP1 (0.34) | CXCR3TDP1MMEL1CES1NCEH1 | |
| SCHEMBL4679605 | 0.83 | TDP1 (0.34) | CXCR3TDP1MMEL1CES1NCEH1 | |
| SCHEMBL4674402 | 0.81 | PTGDR2 (0.35) | CXCR3MMEL1CES1NCEH1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068695-A1 | Inhibitor for enzyme having two divalent metal ions as active center | KIYAMA RYUICHI | 2010-03-18 | — | — | US | disclosed |
| EP-1142872-B1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-6831177-B1 | Preparation of their intermediates, 2-acyl-5-benzylfuran derivatives and 1,2,4-triazole-3- carboxylic acid ester derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| US-20040039060-A1 | Inhibitor for enzyme having two divalent metal ions as active centers | SHIONOGI & CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6645956-B1 | 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment | SHIONOGI & CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6620841-B1 | Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) | SHIONOGI & CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| US-20030171406-A1 | Medicinal compositions containing propenone derivatives | SHIONOGI & CO., LTD (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1297834-A1 | INHIBITOR FOR ENZYME HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS | SHIONOGI & CO., LTD. (JP) | 2003-04-02 | — | — | EP | disclosed |
| EP-1295879-A1 | MEDICINAL COMPOSITIONS CONTAINING PROPENONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1186599-A1 | NOVEL PROCESSES FOR THE PREPARATION OF SUBSTITUTED PROPENONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
| CN-1335834-A | Aromatic heterocyclic compounds having HIV integrase inhibitory activity | SHIONOGI & CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | CXCR3 1130/4885TDP1 306/4885NPSR1 937/4885 |
| US-20030171406-A1 | Medicinal compositions containing propenone derivatives | RPL17, EBP, SERPINB1 | CXCR3 1182/4885TDP1 2165/4885NPSR1 3111/4885 |
| US-20040039060-A1 | Inhibitor for enzyme having two divalent metal ions as active centers | GAA, CMA1, MMEL1 | CXCR3 4853/4885TDP1 1969/4885NPSR1 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.